Paul B. Chapman
Memorial Sloan Kettering Cancer Center(US)Cornell University(US)Townsville Hospital(AU)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses, CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation(2011)7,653 cited
- → Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET(2012)3,679 cited
- → Inhibition of Mutated, Activated BRAF in Metastatic Melanoma(2010)3,526 cited
- → Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial(2012)2,954 cited
- → Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma(2010)1,815 cited
- → Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion(2012)1,730 cited